top
HOME PAGE

Treatment > Blood Diseases and Disorders


Brain Tumors


Piastra M, Di Rocco C, Caresta E, Zorzi G, De Luca D, Caldarelli M, La Torre G, Conti G, Antonelli M, Eaton S, Pietrini D
Blood loss and short-term outcome of infants undergoing brain tumour removal
J Neurooncol. 2008 Jul 10; [Epub ahead of print]
 Abstract |  Links | BL 7:14


Glioblastoma


van Durme CM, Idema RN, van Guldener C.
Two rare complications of glioblastoma multiforme: persistent hiccup and acquired haemophilia A
Neth J Med. 2008 Jul-Aug;66(7):286-8
 Abstract |   Reprint |  Links | BL 7:15


Gliomas


Shah GD, Silver JS, Rosenfeld SS, Gavrilovic IT, Abrey LE, Lassman AB.
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
J Neurooncol. 2007 Jun 27; [Epub ahead of print]
PMID: 17594055 [PubMed - as supplied by publisher]

Singhal N, Selva-Nayagam S, Brown MP. Links | BL 7:6


G


J A Glaspy, J S Jadeja, G Justice, J Kessler, D Richards, L Schwartzberg, NS Tchekmedyian, S Armstrong, J O'Byrne,
G Rossi and A B Colowick
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated withcancer chemotherapy
British Journal of Cancer, 29 July 2002, Volume 87, Number 3, Pages 268-276
Abstract |
Links | BL 1:1

Michael S. Gordon
Managing Anemia in the Cancer Patient: Old Problems, Future Solutions
The Oncologist, Vol. 7, No. 4, 331-341, August 2002
 Abstract |  Full Text |  Reprint |  Links | BL 1:3

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

Ann Oncol 2003 Jan;14(1):29-35



K


Hans-Peter Kiem, Tobias Neff, Brian C. Beard, Laura J. Peterson, Bobbie M. Thomasson, Jess Thompson
Gene Therapy To Protect Hematopoietic Cells From Cytotoxic Chemotherapy In A Clinically Relevant Large Animal Model
Proceedings of the AACR, Volume 45, March 2004, Abstract Number: LB-284

Kuttan G, Kuttan R
Reduction of leukopenia in mice by "viscum album" administration during radiation and chemotherapy
Tumori 1993 Feb 28;79(1):74-6


L


Lenartz D, Stoffel B, Menzel J, Beuth J.
Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients
Anticancer Res 1996 Nov-Dec;16(6B):3799-802


Oligodendroglioma


Vanita Noronha, Nancy Berliner, Karen K. Ballen, Jill Lacy, Jean Kracher, Joachim Baehring and John W. Henson
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature
Neuro-oncol 2006 Jul 1; 8(3):280-283; Epub 2006 May 25
Abstract


R


Bassem I. Razzouk, Jeffrey D. Hord, Marilyn Hockenberry, Pamela S. Hinds, James Feusner, Denise Williams, Wayne R. Rackoff
Double-Blind, Placebo-Controlled Study of Quality of Life, Hematologic End Points, and Safety of Weekly Epoetin Alfa in Children With Cancer Receiving Myelosuppressive Chemotherapy
Journal of Clinical Oncology, Vol 24, No 22 (August 1), 2006: pp. 3583-3589, DOI: 10.1200/JCO.2005.03.4371


S


Salvatore Siena, Simona Secondino, Laura Giannetta, Ornella Carminati and Paolo Pedrazzoli
Optimising management of neutropenia and anaemia in cancer chemotherapy––advances in cytokine therapy
Critical Reviews in Oncology/Hematology, Vol. 48, Suppl. 1, 15 Oct. 2003, Pages S39-S47 (Review Article, Abstract)

David P. Steensma, Roy Molina, Jeff A. Sloan, Daniel A. Nikcevich, Paul L. Schaefer, Kendrith M. Rowland, Jr, Todor Dentchev, Paul J. Novotny, Loren K. Tschetter, Steven R. Alberts, Thomas F. Hogan, Amy Law, Charles L. Loprinzi
Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer
Journal of Clinical Oncology, Vol 24, No 7 (March 1), 2006: pp. 1079-1089; DOI: 10.1200/JCO.2005.02.7276
Abstract | Full Text | Reprint | News


Z


Benny Chung-Ying Zee
Planned Equivalence or Noninferiority Trials Versus Unplanned Noninferiority Claims: Are They Equal
Journal of Clinical Oncology, Vol 24, No 7 (March 1), 2006: pp. 1026-1028; DOI: 10.1200/JCO.2005.04.9684
Full Text | Reprint

 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
| BrainLife Newsletter |
Children's Corner | E-mail Alerts | Journals | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP bottom